Abstract
The role of hepatitis C virus (HCV) infection in the development of vascular disease is controversial. Insulin resistance (IR) is a recognized risk factor for cardiovascular disease (CVD) and is associated with chronic hepatitis C (CHC). Thus, IR may promote atherosclerosis and vascular disease in CHC patients. HCV-associated IR may also cause hepatic steatosis and resistance to antiviral treatment. In addition, HCV may contribute a direct, proatherogenetic action on the vascular wall. This review considers the impact of IR on interferon-α based therapy of HCV infection and the role of insulin-sensitizing agents on the response to antiviral treatment and prevention of IR complications, including CVD.
Keywords: Hepatitis C, insulin resistance, interferon-α, vascular disease, oxidative stress, Interferon (INF), interferon-receptor, Jak/STAT, ISGF3, HOMA-IR, SOCS3, protein phosphatase 2A, PIAS1, protein arginine methyl-transferase (PRMT1), B kinase-beta (IKK), Etanercept, TNF-protein, T1DM, T2DM, HEPATIC STEATOSIS (HS), metabolic steatosis, non alcoholic fatty liver disease, Thiazolidinediones, pioglitazone, rosiglitazone, peroxisome proliferator activated receptors, PPAR- mRNA, STATIN THERAPY AND CHC
Current Pharmaceutical Design
Title: Chronic Hepatitis C, Insulin Resistance and Vascular Disease
Volume: 16 Issue: 34
Author(s): Andreja Trpkovic, Edith Stokic, Djordje Radak, Zoran Gluvic, Mohamed Haidara, Dimitri P. Mikhailidis and Esma R. Isenovic
Affiliation:
Keywords: Hepatitis C, insulin resistance, interferon-α, vascular disease, oxidative stress, Interferon (INF), interferon-receptor, Jak/STAT, ISGF3, HOMA-IR, SOCS3, protein phosphatase 2A, PIAS1, protein arginine methyl-transferase (PRMT1), B kinase-beta (IKK), Etanercept, TNF-protein, T1DM, T2DM, HEPATIC STEATOSIS (HS), metabolic steatosis, non alcoholic fatty liver disease, Thiazolidinediones, pioglitazone, rosiglitazone, peroxisome proliferator activated receptors, PPAR- mRNA, STATIN THERAPY AND CHC
Abstract: The role of hepatitis C virus (HCV) infection in the development of vascular disease is controversial. Insulin resistance (IR) is a recognized risk factor for cardiovascular disease (CVD) and is associated with chronic hepatitis C (CHC). Thus, IR may promote atherosclerosis and vascular disease in CHC patients. HCV-associated IR may also cause hepatic steatosis and resistance to antiviral treatment. In addition, HCV may contribute a direct, proatherogenetic action on the vascular wall. This review considers the impact of IR on interferon-α based therapy of HCV infection and the role of insulin-sensitizing agents on the response to antiviral treatment and prevention of IR complications, including CVD.
Export Options
About this article
Cite this article as:
Trpkovic Andreja, Stokic Edith, Radak Djordje, Gluvic Zoran, Haidara Mohamed, P. Mikhailidis Dimitri and R. Isenovic Esma, Chronic Hepatitis C, Insulin Resistance and Vascular Disease, Current Pharmaceutical Design 2010; 16 (34) . https://dx.doi.org/10.2174/138161210794455067
DOI https://dx.doi.org/10.2174/138161210794455067 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research Dissecting the Mechanisms of Thrombogenesis and Atherosclerosis for Neurodegenerative Disorders
Current Neurovascular Research Multidimensional Targeting: Using Physical and Chemical Forces in Unison
Current Pharmaceutical Biotechnology Telmisartan Blocks Advanced Glycation End Product (AGE)-Induced Plasminogen Activator Inhibitor-1 (PAI-1) Gene Expression in Endothelial Cells via Activation of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ )
Letters in Drug Design & Discovery Cholesterol Ester Transfer Protein (CETP), Postprandial Lipemia and Hypolipidemic Drugs
Current Medicinal Chemistry New Strategies for Managing Anemia of Chronic Kidney Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia
Current Vascular Pharmacology Controlled Release Inhalable Polymeric Microspheres for Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design Hypersensitivity Reactions to Neuromuscular Blocking Agents
Current Pharmaceutical Design Anesthetic Considerations for Electroconvulsive Therapy-Especially Hemodynamic and Respiratory Management
Current Psychiatry Reviews Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design Antioxidant Agents in Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry HDL Therapy for the Treatment of Cardiovascular Diseases
Current Vascular Pharmacology Combining Diffusion-Weighted Imaging Patterns with ABCD2 Score Predicts Stroke Risk after Transient Ischemic Attack
Current Neurovascular Research Myocardial Cellular Damage and Antioxidant Status in Off-Pump Versus On-Pump Coronary Artery Bypass Grafting - A Prospective Study
Vascular Disease Prevention (Discontinued) Big Science for Small Cells: Systems Approaches for Platelets
Current Drug Targets Lithium and Kidney, 60 Years Later
Current Drug Safety Pulmonary Hypertension and Systemic Diseases
Current Drug Targets - Inflammation & Allergy Angiotensin (1-7) and other Angiotensin Peptides
Current Pharmaceutical Design Therapeutic Interventions to Renin-Angiotensin-Aldosterone System, and Vascular Redox State
Recent Patents on Cardiovascular Drug Discovery